Avenue Therapeutics, Inc.
ATXI
$0.773
-$0.1725-18.24%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -28.60% | 63.17% | 33.74% | -66.23% | 147.55% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 52.61% | -28.04% | -42.34% | -45.83% | 211.92% |
| Operating Income | -52.61% | 28.04% | 42.34% | 45.83% | -211.92% |
| Income Before Tax | -701.75% | 32.74% | 42.79% | 17.75% | 177.49% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -701.75% | 32.74% | 42.79% | 17.75% | 177.49% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -15.38% | 0.00% | -86.36% | -54.90% | -- |
| Net Income | -684.79% | 32.82% | 42.41% | 11.30% | 179.46% |
| EBIT | -52.61% | 28.04% | 42.34% | 45.83% | -211.92% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -139.55% | 83.40% | 84.84% | -76.48% | 114.35% |
| Normalized Basic EPS | -138.88% | 93.79% | 92.37% | -77.19% | 114.56% |
| EPS Diluted | -139.55% | 83.40% | 84.84% | -76.32% | 114.35% |
| Normalized Diluted EPS | -138.88% | 93.79% | 92.37% | -77.19% | 114.56% |
| Average Basic Shares Outstanding | 1,378.93% | 981.04% | 657.41% | 373.17% | 454.87% |
| Average Diluted Shares Outstanding | 1,378.93% | 981.04% | 657.41% | 373.17% | 454.87% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
